<H1>Chapter DOI: 10.1007/s00105-014-3575-8<br/>Cited-By Count: 2</H1><table border="1" width="30%"><tr><td>Total References</td><td>31</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>30</td></tr><tr><td>BibStructured Count</td><td width="10%">31</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>27</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>3</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>3</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Baquerizo Nole KL, Yim E, Keri JE (2014) Probiotics and prebiotics in dermatology. J Am Acad Dermatol 71:814&#8211;821</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2014.04.050>10.1016/j.jaad.2014.04.050</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Beck LA, Thaci D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130&#8211;139</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1314768>10.1056/NEJMoa1314768</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Belloni B, Ziai M, Lim A et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120:1223&#8211;1225</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2007.08.060>10.1016/j.jaci.2007.08.060</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Bieber T, Straeter B (2015) Off-label prescriptions for atopic dermatitis in Europe. Allergy 70:6&#8211;11</td><td><a href=http://dx.doi.org/10.1111/all.12498>10.1111/all.12498</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Eyerich S, Onken AT, Weidinger S et al (2011) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. N Engl J Med 365:231&#8211;238</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1104200>10.1056/NEJMoa1104200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Gueniche A, Knaudt B, Schuck E et al (2008) Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 159:1357&#8211;1363</td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2008.08836.x>10.1111/j.1365-2133.2008.08836.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Haeck IM, Knol MJ, Ten Berge O et al (2011) Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 64:1074&#8211;1084</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2010.04.027>10.1016/j.jaad.2010.04.027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Hamilton JD, Suarez-Farinas M, Dhingra N et al (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134:1293&#8211;1300</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2014.10.013>10.1016/j.jaci.2014.10.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Harskamp CT, Armstrong AW (2013) Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg 32:132&#8211;139</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Heil PM, Maurer D, Klein B et al (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course &#8211; a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8:990&#8211;998</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2010.07497.x>10.1111/j.1610-0387.2010.07497.x</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Ibler KS, Jemec GB (2014) Novel investigational therapies for atopic dermatitis. Expert Opin Investig Drugs 24:1&#8211;8</td><td><a href=http://dx.doi.org/10.1517/13543784.2015.957756>10.1517/13543784.2015.957756</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, VolumeID, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Jacobi A, Manger B, Schuler G et al (2003) Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J Dtsch Dermatol Ges 1:259&#8211;272</td><td><a href=http://dx.doi.org/10.1046/j.1610-0387.2003.02044.x>10.1046/j.1610-0387.2003.02044.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Kaesler S, Volz T, Skabytska Y et al (2014) Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol 134:92&#8211;99</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2014.02.017>10.1016/j.jaci.2014.02.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Lane JE, Cheyney JM, Lane TN et al (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54:68&#8211;72</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2005.09.030>10.1016/j.jaad.2005.09.030</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Mrowietz U, Klein CE, Reich K et al (2009) Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 7:474&#8211;479</td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2009.07077.x>10.1111/j.1610-0387.2009.07077.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, FirstPage, VolumeID, Author_FamilyName_1, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Navarini AA, French LE, Hofbauer GF (2011) Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 128:1128&#8211;1130</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2011.09.009>10.1016/j.jaci.2011.09.009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>O&#8217;Regan GM, Sandilands A, McLean WH et al (2009) Filaggrin in atopic dermatitis. J Allergy Clin Immunol 124:R2&#8211;R6</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2009.07.013>10.1016/j.jaci.2009.07.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Oldhoff JM, Darsow U, Werfel T et al (2006) No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 141:290&#8211;294</td><td><a href=http://dx.doi.org/10.1159/000095299>10.1159/000095299</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Puya R, Alvarez-Lopez M, Velez A et al (2012) Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 51:115&#8211;116</td><td><a href=http://dx.doi.org/10.1111/j.1365-4632.2011.05195.x>10.1111/j.1365-4632.2011.05195.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Ring J, Alomar A, Bieber T et al (2012) Guidelines for treatment of atopic eczema (atopic dermatitis). Part II. J Eur Acad Dermatol Venereol 26:1176&#8211;1193</td><td><a href=http://dx.doi.org/10.1111/j.1468-3083.2012.04636.x>10.1111/j.1468-3083.2012.04636.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Schmitt J, Schakel K, Schmitt N et al (2007) Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 87:100&#8211;111</td><td><a href=http://dx.doi.org/10.2340/00015555-0207>10.2340/00015555-0207</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Sediva A, Kayserova J, Vernerova E et al (2008) Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 121:1515&#8211;1516 (author reply 6&#8211;7)</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2008.03.007>10.1016/j.jaci.2008.03.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Sheinkopf LE, Rafi AW, Do LT et al (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29:530&#8211;537</td><td><a href=http://dx.doi.org/10.2500/aap.2008.29.3160>10.2500/aap.2008.29.3160</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Simon D, Hosli S, Kostylina G et al (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121:122&#8211;128</td><td><a href=http://dx.doi.org/10.1016/j.jaci.2007.11.016>10.1016/j.jaci.2007.11.016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Volz T, Skabytska Y, Guenova E et al (2014) Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 134:96&#8211;104</td><td><a href=http://dx.doi.org/10.1038/jid.2013.291>10.1038/jid.2013.291</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Wang WL, Li HY, Zhang MS et al (2013) Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. Int Arch Allergy Immunol 160:18&#8211;26</td><td><a href=http://dx.doi.org/10.1159/000341665>10.1159/000341665</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Weisenseel P, Reich K (2013) Paradoxical skin reactions under therapy with TNF-alpha antagonists. Z Rheumatol 72:423&#8211;428</td><td><a href=http://dx.doi.org/10.1007/s00393-012-1127-0>10.1007/s00393-012-1127-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455&#8211;2466</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1304048>10.1056/NEJMoa1304048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Werfel T (2009) The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 129:1878&#8211;1891</td><td><a href=http://dx.doi.org/10.1038/jid.2009.71>10.1038/jid.2009.71</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Werfel T, Aberer W, Augustin M et al (2009) Atopic dermatitis: S2 guidelines. J Dtsch Dermatol Ges 7(Suppl 1):S1&#8211;S46</td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2008.06981.x>10.1111/j.1610-0387.2008.06981.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Wilson SR, The L, Batia LM et al (2013) The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155:285&#8211;295</td><td><a href=http://dx.doi.org/10.1016/j.cell.2013.08.057>10.1016/j.cell.2013.08.057</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>